Alpha Emitter Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opportunity 2024-32
                     Global Alpha Emitter 
Market Research and 
Forecast Report 2024-
2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
In ternat ional  Market  Analys is  Research and Consul t ing Group is  a leading adv iser  on management  
s t rategy and market  research wor ldwide.  We par tner  wi th c l ients  in  a l l  regions and indust ry  
vert ica ls  to  ident i fy  thei r  h ighest -value oppor tuni t ies,  address thei r  most  cr i t ica l  chal lenges,  and 
t ransform thei r  bus inesses.
IMARC’s in format ion products  inc lude major market ,  sc ient i f ic ,  economic and technological  
developments  for  bus iness leaders  in  pharmaceut ica l ,  indust r ia l ,  and h igh technology 
organizat ions.  Market  forecasts  and indust ry  analys is  for  b iotechnology,  advanced mater ia ls ,  
chemicals ,  food and beverage,  t ravel  and tour ism, nanotechnology and novel  process ing methods 
are at  the top of  the company’s  exper t ise.
IMARC’s ta i lored approach combines unfathomable ins ight  in to the dynamics o f  companies and 
markets wi th c lose cooperat ion at  a l l  levels  of  the c l ient  organizat ion.  This ensures that  our  c l ients 
achieve unmatchable compet i t ive advantage,  bui ld  more pro f ic ient  organizat ions,  and secure 
las t ing resul ts .
Accord ing  to  the  la tes t  repor t  by  IMARC Group,  t i t l ed  "Alpha Emit ter  
Market :  Global  Industry  Trends,  Share ,  S ize ,  Growth ,  Opportuni ty  and 
Forecast  2024-2032,"  the  g loba l  a lpha  emi t te r  market  s ize  reached US$ 
1,476 .8  M i l l i on  in  2023.
Factors Affecting the Growth of the Alpha Emitter  Industry:
Report Increasing Demand in Medical  Appl icat ions:
Alpha emi t ters  a re  ga in ing t rac t ion in  the  f ie ld  o f  onco logy ,  ma in ly  in  
Highlight and ta rge ted a lpha  therapy (TAT)  fo r  cancer  t reatment .  TAT invo lves the  use  o f  
a lpha-emi t t ing  rad ionuc l ides  to  se lec t i ve ly  de l i ve r  rad ia t ion to  cancer  ce l l s  
wh i le  min im iz ing  damage to  sur round ing  hea l thy  t issues .  
Description Moreover ,  a lpha  emi t ters  are  showing the  ab i l i t y  to  t rea t  tumors  tha t  are  
res is tan t  to  o ther  fo rms o f  t reatment .  The i r  h igh  l inear  energy t rans fer  (LET)  
enab les  them to  induce  DNA damage in  cancer  ce l ls ,  lead ing to  ce l l  dea th .  
Th is  e f fec t i veness  in  combat ing res is tant  tumors  i s  spur r ing  in te res t  and 
demand among hea l thcare  p rov iders  and  pa t ien ts  seek ing  a l terna t ive  
t rea tment  opt ions.
Technological  Advancements:
Innova t ions  in  techno logy  i s  l ead ing  to  the  deve lopment  o f  more  p rec ise  
ta rge t ing  and  de l ive ry  sys tems fo r  a lpha  emi t te rs .  Th is  inc ludes  the  des ign  o f  
nove l  t a rge t ing  mo lecu les ,  such  as  an t ibod ies  and  pep t ides ,  wh ich  enab le  the  
Report se lec t i ve  de l i ve ry  o f  a lpha-emi t t i ng  rad ionuc l ides  to  cancer  ce l l s  wh i le  spar ing  
hea l thy  t i ssues .  
Highlight and These  advancements  inc rease  the  e f f i cacy  o f  a lpha  the rapy  and  reduce  o f f -ta rge t  e f fec ts .  Fur the rmore ,  techno log ica l  advancements  in  imag ing  moda l i t ies  
and  dos imet ry  me thods  a re  improv ing  the  v isua l i za t ion  and  quan t i f i ca t ion  o f  
Description a lpha  emi t te r  d i s t r ibu t ion  w i th in  the  body ,  wh ich  a l lows  hea l thca re  p rov ide rs  to  
assess  t rea tment  response  be t te r ,  op t imize  dos ing  reg imens ,  and  ensu re  
pa t ien t  sa fe ty .
Support ive Regulatory Environment:
Regu la to ry  agenc ies  p lay  a  c r i t i ca l  ro le  in  eva lua t ing  the  sa fe ty  and  e f f i cacy  o f  
a lpha  emi t te rs  fo r  med ica l  use .  A  suppor t i ve  regu la to ry  env i ronment  en ta i l s  
c lea r  and  e f f i c ien t  approva l  p rocesses  tha t  enab le  manu fac tu re rs  to  b r ing  new 
a lpha-emi t t i ng  p roduc ts  to  marke t .
St reaml ined  p rocesses  reduce  regu la to ry  ba r r ie rs  and  uncer ta in t ies ,  
encou rag ing  inves tment  in  research  and  deve lopment  (R&D)  ac t i v i t ies .  
Add i t iona l l y ,  a  suppo r t i ve  regu la to ry  env i ronment  recogn izes  the  c l in i ca l  
bene f i t  o f  a lpha  emi t te rs  in  med ica l  app l ica t ions ,  pa r t i cu la r ly  i n  a reas  l i ke  
ta rge ted  a lpha  the rapy  (TAT)  fo r  cancer  t rea tment .  Regu la to ry  agenc ies  
Report eva lua te  c l i n ica l  da ta  to  assess  the  the rapeu t ic  va lue  o f  a lpha-emi t t i ng  
p roduc ts  and  de te rmine  the i r  p lace  in  c l in ica l  p rac t i ce .
Highlight and 
Request  for  a  PDF sample  o f  th is  repor t :  
h t tps : / /www. imarcgroup .com/a lpha-emi t te r -marke t / reques tsamp le
Description
Report Description
Global Alpha Emitter Market Trends:
Patient advocacy groups and heal thcare organizations are playing a signi f icant ro le in rais ing 
awareness about a lpha therapy, advocat ing for  access to innovat ive treatments,  and support ing 
pat ient-centr ic  care (PCC) models.  Pat ient involvement in treatment decis ion-making and 
research ini t iat ives shapes market t rends and inf luences heal thcare pol ic ies.  
In addi t ion, the growing integrat ion of  alpha emit ters wi th complementary treatment modal i t ies,  
such as chemotherapy, immunotherapy, and external  beam radiat ion therapy, to enhance 
treatment outcomes, overcome resistance mechanisms, and minimize toxic i ty  is posi t ively 
inf luencing the market.
View Report TOC, Figures and Tables :  https://www.imarcgroup.com/alpha-emitter-market
Breakup by Type of Radionuclide:
• Astat ine
• Radium
• Actinium
• Lead
• Bismuth
Report • Others
Segmentation
Breakup by Medical Application:
• Prostate Cancer
• Bone Metastasis
• Ovarian Cancer
• Pancreat ic Cancer
• Endocr ine Tumors
• Others
Breakup by End User:
• Hospitals
• Medical  Research Insti tut ions
• Others
Report 
Segmentation Breakup by Region:
• North America
• Asia-Pacifi c
• Europe
• Latin America
• Middle East and Afr ica
• Actinium Pharmaceuticals Inc.
• Alpha Tau Medical  Ltd.
• Bayer AG
Competitive • Fusion Pharmaceuticals
• IBA RadioPharma Solutions
Landscape 
• RadioMedix Inc.
with Key 
Players
What was the size of the global alpha emitter 
market in 2023?
What is the expected growth rate of the global 
alpha emitter market during 2024-2032?
What are the key factors driving the global alpha 
Key emitter market?
Questions What has been the impact of COVID-19 on the 
global alpha emitter market?
Answered in 
What is the breakup of the global alpha emitter 
the Report market based on the type of radionuclide?
What is the breakup of the global alpha emitter 
market based on the medical application?
What are the key regions in the global alpha 
emitter market?
Who are the key players/companies in the global 
alpha emitter market?
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
Table of         2 . 4 . 1     B o t t o m - U p  A p p r o a c h        2 . 4 . 2     T o p - D o w n  A p p r o a c h
    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4     I n t r o d u c t i o n
Contents     4 . 1     O v e r v i e w    4 . 2     K e y  I n d u s t r y  T r e n d s5     G l o b a l  A l p h a  E m i t t e r  M a r k e t
    5 . 1     M a r k e t  O v e r v i e w
    5 . 2     M a r k e t  P e r f o r m a n c e
    5 . 3     I m p a c t  o f  C O V I D - 1 9
    5 . 4     M a r k e t  F o r e c a s t
6      M a r k e t  B r e a k u p  b y  T y p e  o f  R a d i o n u c l i d e
    6 . 1     A s t a t i n e  
        6 . 1 . 1  M a r k e t  T r e n d s
        6 . 1 . 2  M a r k e t  F o r e c a s t
    6 . 2     R a d i u m  
        6 . 2 . 1  M a r k e t  T r e n d s
        6 . 2 . 2  M a r k e t  F o r e c a s t
    6 . 3     A c t i n i u m  
        6 . 3 . 1  M a r k e t  T r e n d s
        6 . 3 . 2  M a r k e t  F o r e c a s t
       
   6 . 4     L e a d  
        6 . 4 . 1  M a r k e t  T r e n d s
        6 . 4 . 2  M a r k e t  F o r e c a s t
    6 . 5     B i s m u t h  
        6 . 5 . 1  M a r k e t  T r e n d s
        6 . 5 . 2  M a r k e t  F o r e c a s t
    6 . 6     O t h e r s
        6 . 6 . 1  M a r k e t  T r e n d s
        6 . 6 . 2  M a r k e t  F o r e c a s t
7    M a r k e t  B r e a k u p  b y  M e d i c a l  A p p l i c a t i o n
Table of     7 . 1     P r o s t a t e  C a n c e r        7 . 1 . 1  M a r k e t  T r e n d s
        7 . 1 . 2  M a r k e t  F o r e c a s t
Contents     7 . 2     B o n e  M e t a s t a s i s        7 . 2 . 1  M a r k e t  T r e n d s
        7 . 2 . 2  M a r k e t  F o r e c a s t
    7 . 3     O v a r i a n  C a n c e r
        7 . 3 . 1  M a r k e t  T r e n d s
        7 . 3 . 2  M a r k e t  F o r e c a s t
    7 . 4     P a n c r e a t i c  C a n c e r
        7 . 4 . 1  M a r k e t  T r e n d s
        7 . 4 . 2  M a r k e t  F o r e c a s t
    7 . 5     E n d o c r i n e  T u m o r s
        7 . 5 . 1  M a r k e t  T r e n d s
        7 . 5 . 2  M a r k e t  F o r e c a s t
    7 . 6     O t h e r s
        7 . 6 . 1  M a r k e t  T r e n d s
        7 . 6 . 2  M a r k e t  F o r e c a s t
F o r  m o r e  i n f o r m a t i o n ,  v i s i t :  
ht t ps : / /w ww. i ma rc gro up . c o m /a lph a -em i t te r-m a rke t / t o c
Partial List of Clients
Partial List of Clients
Disclaimer
© 2024  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
+1-631-791-1145
[email protected]
Stay With Us: